BDP1 as a biomarker in serous ovarian cancer

TFIIIB, an RNA polymerase III specific transcription factor has been found to be deregulated in human cancers with much of the research focused on the TBP, BRF1, and BRF2 subunits. To date, the TFIIIB specific subunit BDP1 has not been investigated in ovarian cancer but has previously been shown to be deregulated in neuroblastoma, breast cancer, and Non‐Hodgkins lymphoma.

• Publication year

  2022

• Venue

  Cancer Medicine

• Publication date

  2022-10-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cam4.5388PMID 36305848PMCID 10028122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2022

  2022cited by this paper
• BDP1 Alterations Correlate with Clinical Outcomes in Breast Cancer

  2022cited by this paper
• BDP1 Expression Correlates with Clinical Outcomes in Activated B-Cell Diffuse Large B-Cell Lymphoma

  2022cited by this paper
• BDP1 as a biomarker in serous ovarian cancer

  2022cited by this paper
• BDP1 Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study

  2021cited by this paper
• RNA polymerase III is required for the repair of DNA double-strand breaks by homologous recombination.

  2021cited by this paper
• Treatment of epithelial ovarian cancer

  2020cited by this paper
• A meta-analysis of BRF2 as a prognostic biomarker in invasive breast carcinoma

  2020cited by this paper
• Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.

  2020cited by this paper
• Somatic mutations of cancer-related genes PELP1 and BDP1 in colorectal cancers.

  2020cited by this paper
• CA125 and Ovarian Cancer: A Comprehensive Review

  2020cited by this paper
• Alcohol Intake and Abnormal Expression of Brf1 in Breast Cancer

  2019cited by this paper
• GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis

  2019cited by this paper
• ShinyGO: a graphical gene-set enrichment tool for animals and plants

  2019cited by this paper
• The GTEx Consortium atlas of genetic regulatory effects across human tissues

  2019cited by this paper
• Standards for design and measurement would make clinical research reproducible and usable

  2018cited by this paper
• Ovarian cancer statistics, 2018

  2018cited by this paper
• BRF2 as a promising indicator for radical lymph-node dissection surgery in patients with cN0 squamous cell carcinoma of the middle thoracic esophagus

  2018cited by this paper
• Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13

  2018cited by this paper
• GOnet: a tool for interactive Gene Ontology analysis

  2018cited by this paper
• Association Between Germline Mutations in BRF1, a Subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer.

  2018cited by this paper
• Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway

  2018cited by this paper
• Double agents: genes with both oncogenic and tumor-suppressor functions

  2018cited by this paper
• Molecular mechanisms of Bdp1 in TFIIIB assembly and RNA polymerase III transcription initiation

  2017cited by this paper
• GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

  2017cited by this paper
• Role of Brf1 interaction with ERα, and significance of its overexpression, in human breast cancer

  2017cited by this paper
• mutation in ovarian cancer: testing, implications and treatment considerations.

  2017cited by this paper
• Epidemiology of ovarian cancer: a review

  2017cited by this paper
• BRCA mutation in ovarian cancer: testing, implications and treatment considerations

  2017cited by this paper
• TP53 Mutations in Breast and Ovarian Cancer.

  2017cited by this paper
• Ras/ERK-signalling promotes tRNA synthesis and growth via the RNA polymerase III repressor Maf1 in Drosophila

  2016cited by this paper
• Web-TCGA: an online platform for integrated analysis of molecular cancer data sets

  2016cited by this paper
• The eukaryotic promoter database in its 30th year: focus on non-vertebrate organisms

  2016cited by this paper
• The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinical–genomic driver associations

  2015cited by this paper
• Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes

  2015cited by this paper
• Targeting c-MYC in Platinum-Resistant Ovarian Cancer

  2015cited by this paper
• Architecture of TFIIIC and its role in RNA polymerase III pre-initiation complex assembly

  2015cited by this paper
• BRF1 mutations alter RNA polymerase III–dependent transcription and cause neurodevelopmental anomalies

  2015cited by this paper
• TFIIB-Related Factor 2 Over Expression Is a Prognosis Marker for Early-Stage Non-Small Cell Lung Cancer Correlated with Tumor Angiogenesis

  2014cited by this paper
• TFIIB-Related Factor 2 Is Associated with Poor Prognosis of Nonsmall Cell Lung Cancer Patients through Promoting Tumor Epithelial-Mesenchymal Transition

  2014cited by this paper
• Gene Expression Analysis in Ovarian Cancer – Faults and Hints from DNA Microarray Study

  2014cited by this paper
• Overexpression of TFIIB-related factor 2 is significantly correlated with tumor angiogenesis and poor survival in patients with esophageal squamous cell cancer

  2013cited by this paper
• Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

  2013cited by this paper
• The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

  2012cited by this paper
• Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients.

  2012cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response

  2011cited by this paper
• RNA polymerase III transcription in cancer: the BRF2 connection

  2011cited by this paper
• Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

  2011cited by this paper
• Inhibition of U6 snRNA Transcription by PTEN.

  2010cited by this paper
• Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma

  2010cited by this paper
• Regulation of TFIIIB during F9 cell differentiation

  2010cited by this paper
• Treatment for Recurrent Ovarian Cancer—At First Relapse

  2009cited by this paper
• The JNKs differentially regulate RNA polymerase III transcription by coordinately modulating the expression of all TFIIIB subunits

  2009cited by this paper
• Yin Yang 1 Modulates Taxane Response in Epithelial Ovarian Cancer

  2009cited by this paper
• Inhibition of RNA polymerase III transcription by BRCA1.

  2009cited by this paper
• TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

  2008cited by this paper
• PTEN Represses RNA Polymerase III-Dependent Transcription by Targeting the TFIIIB Complex

  2008cited by this paper
• Differential expression of the TFIIIB subunits Brf1 and Brf2 in cancer cells

  2008cited by this paper
• Genomic analysis of the 8p11‐12 amplicon in familial breast cancer

  2007cited by this paper
• CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.

  2006cited by this paper
• Spatial organization of transcription by RNA polymerase III

  2006cited by this paper
• BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

  2005cited by this paper
• A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes

  2005cited by this paper
• The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin

  2004cited by this paper
• CK2 phosphorylation of Bdp1 executes cell cycle-specific RNA polymerase III transcription repression.

  2004cited by this paper
• RNA polymerase III transcription and cancer

  2004cited by this paper
• Direct Regulation of RNA Polymerase III Transcription by RB, p53 and c-Myc

  2003cited by this paper
• Signal transduction pathways of taxanes-induced apoptosis.

  2003cited by this paper
• Direct activation of RNA polymerase III transcription by c-Myc

  2003cited by this paper
• TFIIIB is phosphorylated, disrupted and selectively released from tRNA promoters during mitosis in vivo

  2003cited by this paper
• Recruitment of RNA polymerase III to its target promoters.

  2002cited by this paper
• Genes for human general transcription initiation factors TFIIIB, TFIIIB-associated proteins, TFIIIC2 and PTF/SNAPC: functional and positional candidates for tumour predisposition or inherited genetic diseases?

  2001cited by this paper
• Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3

  2001cited by this paper
• RNA polymerase III transcription factor TFIIIC2 is overexpressed in ovarian tumors.

  2000cited by this paper
• Different human TFIIIB activities direct RNA polymerase III transcription from TATA-containing and TATA-less promoters.

  2000cited by this paper
• Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

  2000cited by this paper
• A stable complex of a novel transcription factor IIB- related factor, human TFIIIB50, and associated proteins mediate selective transcription by RNA polymerase III of genes with upstream promoter elements.

  2000cited by this paper
• p53 is a general repressor of RNA polymerase III transcription

  1998cited by this paper
• Transcription factor IIIB: An important determinant of biosynthetic capacity that is targeted by tumour suppressors and transforming proteins.

  1998cited by this paper

• Stemness-driven clusters in ovarian cancer: immune characteristics and prognostic implications

  2025cites this paper
• Maf1 cooperates with progesterone receptor to repress RNA polymerase III transcription of select tRNAs

  2025cites this paper
• The importance of protein domain mutations in cancer therapy

  2024cites this paper
• MAF1 is a predictive biomarker in HER2 positive breast cancer

  2023influential citation
• BDP1 as a biomarker in serous ovarian cancer

  2022cites this paper